68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients

Last updated: February 18, 2023
Sponsor: Wuhan Union Hospital, China
Overall Status: Active - Recruiting

Phase

1

Condition

Neoplasms

Treatment

N/A

Clinical Study ID

NCT05490849
XLan-0799
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Angiogenesis is essential in tumor growth, proliferation, progression, and metastasis. Overexpression of aminopeptidase N (APN/CD13) and/or integrin αvβ3 in endothelial and tumor cells is an essential marker of tumor-associated angiogenesis. It is highly expressed in malignant tissues such as ovarian and pancreatic cancer but less expressed in normal tissues. Therefore, CD13 and αvβ3 are important targets for diagnosis and efficacy assessment in ovarian and pancreatic cancer. Single receptor targeting probes have many disadvantages, such as relatively low binding affinity, short tumor retention time, and low tumor uptake. RGD (Arg-Gly-Asp) and NGR (Asp-Gly-Arg) are recognized peptide sequences targeting CD13 or αvβ3. PET imaging with 68Ga-HX01, a radionuclide 68Ga labeled peptide isomer formed from RGD and NGR, can be helpful for targeted diagnosis and efficacy assessment of malignant tumors.

This project proposes to use 68Ga-HX01 PET imaging in the diagnosis and staging of malignant tumors, i.e., ovarian and pancreatic cancer, and to compare the diagnostic efficacy of 68Ga-HX01 with the pathology gold standard. And this study was conducted to compensate for the lack of value of 18F-FDG PET imaging for the diagnosis and staging of malignant tumors by comparing 68Ga-HX01 with the commonly used 18F-FDG PET imaging.

Eligibility Criteria

Inclusion

Inclusion Criteria: Healthy volunteers:

  1. fully understand and voluntarily sign the informed consent form
  2. male or female, age 18-65 years
  3. body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women; body mass index (BMI) withinthe range of 19.0 to 26.0 kg/m2 (including threshold values)
  4. no history of chronic or severe disorders of the cardiovascular, liver, kidney,pulmonary, blood and lymphatic, endocrine, immunological, mental, neuromuscular, orgastrointestinal systems over the past three years; and good general health
  5. no abnormalities in the evaluation of vital signs and physical exam
  6. have no intention of having children, use effective contraception freely, and have nointention of donating sperm or eggs during the experiment and for six months followingthe trial's completion
  7. be able to communicate effectively with the investigator and to comprehend and adhereto the study's criteria Cancer patients:
  8. The subject or his or her legal guardian may sign the informed consent form
  9. a commitment to comply with the study guidelines and to to work with the investigatorduring the duration of the study
  10. patients with clinically suspected or confirmed, but not tumor-related, ovariancancer, pancreatic cancer, or other malignancies (supporting evidence includes serumrelevant tumor markers, imaging data such as ultrasound, CT, MRI, and histologicalpathological examination) and in good general health
  11. pathological results to be obtained by biopsy or surgical resection

Exclusion

Exclusion Criteria: Healthy volunteers:

  1. allergic body
  2. acute diseases diagnosed before the study
  3. have undergone surgery within 6 months prior to the trial would affect the absorption,distribution, metabolism, or excretion of the drug
  4. have used any medication (including prescription drugs, over-the-counter drugs, herbalmedicines) within 2 weeks prior to the study
  5. pregnant and lactating women Cancer patients:
  6. patients or their legal guardian are unable or unwilling to sign the informed consentform
  7. incapacity to collaborate in the complete implementation of the study
  8. a history of cancer or oncologic treatment
  9. acute systemic diseases and electrolyte disturbances
  10. pregnant or lactating women

Study Design

Total Participants: 100
Study Start date:
October 01, 2021
Estimated Completion Date:
December 31, 2023

Study Description

Malignant tumors are a prevalent cause of death in human diseases that pose a grave threat to human health. The prognosis can be considerably improved by early diagnosis and therapy. Nevertheless, the pathophysiology of various types of tumors varies, and the diagnosis and treatment of tumors continue to provide challenges.

Angiogenesis is essential in tumor growth, proliferation, progression, and metastasis. Overexpression of aminopeptidase N (APN/CD13) and/or integrin αvβ3 in endothelial and tumor cells is an essential marker of tumor-associated angiogenesis. It is highly expressed in malignant tissues such as ovarian and pancreatic cancer but less expressed in normal tissues. Therefore, CD13 and αvβ3 are important targets for diagnosis and efficacy assessment in ovarian and pancreatic cancer. Single receptor targeting probes have many disadvantages, such as relatively low binding affinity, short tumor retention time, and low tumor uptake. RGD (Arg-Gly-Asp) and NGR (Asp-Gly-Arg) are recognized peptide sequences targeting CD13 or αvβ3. PET imaging with 68Ga-HX01, a radionuclide 68Ga labeled peptide isomer formed from RGD and NGR, can be helpful for targeted diagnosis and efficacy assessment of malignant tumors.

This project proposes to use 68Ga-HX01 PET imaging in the diagnosis and staging of malignant tumors, i.e., ovarian and pancreatic cancer, and to compare the diagnostic efficacy of 68Ga-HX01 with the pathology gold standard. And this study was conducted to compensate for the lack of value of 18F-FDG PET imaging for the diagnosis and staging of malignant tumors by comparing 68Ga-HX01 with the commonly used 18F-FDG PET imaging.

Connect with a study center

  • China, Hubei Province

    Wuhan, Hubei 430022
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.